Omega Diagnostics Share Discussion Threads

[dibs61] 26/9/2019 10:49

Interesting article.... and see if you can spot the mention of ODX in there too...

hxxps://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002820

[dibs61] 26/9/2019 09:50

buywell3 - I know some of my fellow investors may not like this but I would actually agree with your post 1903. I think you're right in all your points there. Even if RS wanted to sell who is going to take his stake? But no, for the record, I have NOT sold a single share and remain very optimistic about our longer term prospects.

up - I don't agree with you re Sneller and Harwood. They play the long game.

Sneller is a TOP fund manager. Just check out the long term performance of his funds. Way outperforming his rivals. So, for me, it has always been the cornerstone of my investment here the fact he has put MILLIONS into this company.

I don't have to sell and intend to play this one out. IMHO it WILL pay out in the end.

[buywell3] 25/9/2019 18:50

If you read the results you would see nobody wanted to buy any bits of the company

The profit was only due to the sale of a bit of the company last year , can't be sold twice.

Thus investors are locked in

More money was needed to complete CD4, which could still take longer than envisaged IMO

Stuck is the word that comes to mind

[upomega] 25/9/2019 18:30

Hope your right barry. here is hoping for some decent orders. Not that I would want to see the company sold though

[barrywhit] 25/9/2019 18:19

upomega, I can't see the company being sold for at least a year. To get best value they need to see increased orders from China, more antigens added to the IDS frame and WHO approval for the CD4 products, hence the placing to give them working capital for at least the next 12 months....imo

[upomega] 25/9/2019 17:54

Just noticed that. Maybe the fundraise was more to do with a tidy balance sheet pending a sale of the whole business. Personally I cannot see R Sneller and Harwood sitting by much longer without seeing some real value being added to their investment. Hope I am wrong, but they are investors after all.

[buywell3] 25/9/2019 17:44

That would be a sell then

And without buywell posting once today

[barrywhit] 25/9/2019 17:40

350k delayed trade showing @ 10.5p....

[upomega] 24/9/2019 19:48

With regards to who validation. My understanding is that we are now at the second stage of validation which now involves field trials. As I understand it the final stage is for them to view the manufactoring site. Bear in mind omega has already carried out a number of field trials all of which have been successful

[wigwammer] 24/9/2019 19:19

Stop wasting people's time and filling chat rooms with garbage. End of.

[gwr7] 24/9/2019 16:53

I have no personal grievance with you David. If you try to claim the moral high ground be careful you're not perched on a pole in a coconut shy. I don't think that subsequently deleted post on the SCLP thread was your finest hour, if you are alftupper, but so what? This is the world of advfn, not tea at Claridge's. On this thread I'll stick to facts rather than opinions from now on. I'm sure you know what my opinion is of the board's performance at Omega by now.

[buywell3] 24/9/2019 15:12

ODX will have to have filled in the data requested by the WHO as per this:




I have looked but can't see a RNS from ODX to say they have done this and that ODX CD4 technologies are currently being tested by the WHO as per

Summary of the study protocol for Multicentre Evaluation of CD4 technologies as part of the WHO Prequalification of Diagnostics Programme (PQDx)



I might have missed it so will look again



Just read this

'whilst the Company undergoes the World Health Organisation Prequalification programme.'


so it looks like ODX is currently being looked at by the WHO


Temperature issues have been a problem and buywell went on about these a couple of years back.

IF ODX have not got hteir productsd IMO to operate at sufficiently high enough temps , then IMO the WHO will not pass it

This is what they say :

Product Stability

Product stable to meet "harsh" conditions (hot, wet, dry, dusty)

> Transportation studies (simulate "worst" conditions)
> Long term stability at limiting conditions
> In-use stability studies (open vial)
> Data to support all claims available on-site
> Note: product labelling (component, kit and shipping box)


IMO the ''worst'' conditions will be close to 50 degrees Centigrade as it gets very hot in Africa

Correct me if I am wrong but I seem to remember CD4 was bought up to work/be stored ok at around 40 degrees centigrade .

I don't think that is high enough

All IMO

dyor


Visitect Malaria seems to have disappeared from the website has it been binned ? just found it

As part of our strategic review we made the difficult decision to close down our Indian (Pune) manufacturing facility and withdraw from the regulatory approval process for malaria. The processes were taking longer than we had initially envisaged and, therefore, the operation would have remained loss making for a further 12-18 months which we felt was not sustainable. In addition, this has freed up our regulatory resource to focus on VISITECT® CD4 registrations.

[buywell3] 24/9/2019 14:54

Both of you knockers

Give me 4 instances in the last 3 years when buywell has got it wrong and I will stop posting for 6 months minimum

All must be with my advfn link to the post

2 from each of you


Bet you can't

[wigwammer] 24/9/2019 13:50

True. And when he gets it wrong he just disappears. A total time waster.

[buywell3] 24/9/2019 09:51

buywell has just seen this and in the interest of airing what he thinks is worth reading

This one is an absolute must as I believe it will directly impact ODX very soon

Can anyone confirm that ODX are taking part in this WHO evaluation of CD4 technologies ?




After the studies have been completed, all results will be compiled by WHO, data will be analysed per technology as well as a comparative data set. The analysis will be shared and discussed with the participating laboratories before being finalized. The technology-specific reports will be shared with the respective manufacturers who will be expected to provide comments within 30 days. Final results will then be used in the prequalification programme. A composite report summarizing the results will be published on WHO website.

[longshanks] 24/9/2019 09:42

Furthermore. Clearly, the richer the country, the higher that low count limit will be. Hence a relatively rich country like Nigeria will have more demand for the 350 device, whilst Mali will prefer the 250.It is a troubling ethical dilemma but clearly current thinking is that 250 is the absolute lowest count a patient should reach before commencing viral load treatment.

[buywell3] 24/9/2019 09:40

If you read this then the whole future of CD4 testing has been thrown up into the air

ODX started their work on CD4 prior to its publication



buywell strongly urges any newbe to read it

dyor

[longshanks] 24/9/2019 09:38

Don't mistake existing CD4 testing for testing with the Visitect device.The value of Visitect CD4 is that the user can assess themselves and then refer themselves for viral load treatment when there count reaches a low level. The current process is too expensive and time consuming with patients having to travel for assessment.It is far better to treat all patients with antiretrovirals immediately but the cost is prohibitive for many countries. That is where the CD4 test can help prioritise treatment.

[buywell3] 24/9/2019 09:11

From your comments do you agree then that the 350 test has a limited market ?

The WHO still have to decide on CD4 the way the results read

So these snippets and link from a WHO website does IMO not make the outcome look too good I would have thought

''Recent studies suggest that in situations where viral load is available and patients are virologically suppressed, long-term CD4 monitoring adds little value and stopping CD4 monitoring will have major cost savings.''

'' in settings where both CD4 cell counts and viral load testing are routinely available, countries should consider reducing the frequency of CD4 cell counts or not doing routine CD4 monitoring for patients who are stable on ART.''





I have not seen a link where the WHO have come down in favour of CD4 testing on a regular basis but if somebody else has please post it .


Nobody has commented on the fact that whilst ODX showed a profit this time round

The profit was only because of sales of bits of the company.

Something that can't be repeated again IMO.

[longshanks] 24/9/2019 08:50

I think you will find the focus is on WHO pre-registration of the Advanced disease test (250). That won't cost much and will lead to significant orders funded by international aid programs.

[buywell3] 24/9/2019 08:45

From results it would appear more money is needed 350 test it says

''The 350 test has now been registered in three countries and is in the process of being registered in nine more.

Registration can be both time consuming and complicated in many countries, requiring not only paperwork submissions but also at times in-country clinical evaluations.''

[longshanks] 24/9/2019 08:29

As I understand it the ongoing investment is in the Advanced CD4 test (250) and the country by country validation.That cost though is very much under control I feel and will increasingly be covered by growing sales. There is a large unmet demand for both CD4 tests: Nigeria looks a more significant market for the 350 than others, that is all.

[buywell3] 24/9/2019 07:05

In the results it said this about CD4

'' We continue to regard Nigeria as the largest commercial market for the 350 test.''


My question is

' Do you think the company would have spent and still be spending millions on CD4 if they knew that Nigeria represented the best chance of selling the CD4 test ? '